clinical trial · NCT07142954
Epidemiology and Biomarker Study in Alzheimer's Disease
Eli Lilly and Company·phase3·recruiting·n = 3,400
Alzheimer DiseaseP-tau217 Test
brief summary
Study AACU determines rates of cognitive worsening in participants within elevated and not elevated plasma P-tau217 cohorts. Participation in AACU will last approximately 7 years.
started
Aug 25, 2025
primary completion
Jul 1, 2033
completion
Jul 1, 2033
last updated
May 14, 2026
detailed description
Study AACU is a non-drug interventional study. The intervention is annual plasma P-tau217 testing. Enrollment is anticipated to be approximately 3400 participants.
official title
A Longitudinal, Prospective Epidemiology Study in Alzheimer's Disease: Assessing Neurocognitive and Biomarker Changes and Health Outcomes in Individuals at Risk for Symptoms of Alzheimer's Disease (ANCHOR-AD)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol